Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -86.10% is 51% below its 5-year average of -57.13%, around the middle of its 5-year range (-169.82%–-28.65%).
As of the fiscal period ended Tuesday, June 30, 2026. 28.28% above its 12-month average of -120.04%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -86.10%.
RETURN ON EQUITY (ROE)
-86.10%
RETURN ON EQUITY (ROE) AVG TTM
-120.04%
RETURN ON EQUITY (ROE) AVG 3Y
-78.51%
RETURN ON EQUITY (ROE) AVG 5Y
-57.13%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+28.28%
CURRENT VS 3Y AVG
-9.67%
CURRENT VS 5Y AVG
-50.72%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-37.66%
median of 436 covered companies
CURRENT VS SECTOR MEDIAN
-128.62%
vs the sector median at left
Cabaletta Bio, Inc.
Market Cap
$339.15M
Return on Equity (ROE)
-86.10%
TTM Avg
-120.04%
3Y Avg
-78.51%
5Y Avg
-57.13%
Market Cap
$345.48M
Return on Equity (ROE)
-320.77%
TTM Avg
-82.83%
3Y Avg
-78.63%
5Y Avg
-104.90%
Market Cap
$330.60M
Return on Equity (ROE)
-41.02%
TTM Avg
-44.84%
3Y Avg
-46.96%
5Y Avg
-38.83%
Market Cap
$348.59M
Return on Equity (ROE)
-26.14%
TTM Avg
-53.80%
3Y Avg
-12.25%
5Y Avg
19.21%
Market Cap
$348.85M
Return on Equity (ROE)
N/A
TTM Avg
-12.63%
3Y Avg
-14.73%
5Y Avg
14.28%
Market Cap
$329.01M
Return on Equity (ROE)
-226.56%
TTM Avg
-87.78%
3Y Avg
-55.09%
5Y Avg
-55.09%
Market Cap
$317.09M
Return on Equity (ROE)
-25.73%
TTM Avg
-32.35%
3Y Avg
-2448.72%
5Y Avg
-1749.34%
Market Cap
$361.64M
Return on Equity (ROE)
N/A
TTM Avg
-589.37%
3Y Avg
-290.01%
5Y Avg
-205.39%
Market Cap
$363.54M
Return on Equity (ROE)
N/A
TTM Avg
34.79%
3Y Avg
145.50%
5Y Avg
100.23%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | $339.15M | -86.10% | -120.04% | -78.51% | -57.13% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $345.48M | -320.77% | -82.83% | -78.63% | -104.90% |
| C4 Therapeutics, Inc. (CCCC)vs › | $330.60M | -41.02% | -44.84% | -46.96% | -38.83% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $348.59M | -26.14% | -53.80% | -12.25% | 19.21% |
| Embecta Corp. (EMBC)vs › | $348.85M | N/A | -12.63% | -14.73% | 14.28% |
| CapsoVision, Inc. (CV)vs › | $329.01M | -226.56% | -87.78% | -55.09% | -55.09% |
| Benitec Biopharma Inc. (BNTC)vs › | $317.09M | -25.73% | -32.35% | -2448.72% | -1749.34% |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | -589.37% | -290.01% | -205.39% |
| Agenus Inc. (AGEN)vs › | $363.54M | N/A | 34.79% | 145.50% | 100.23% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $366.39M | -62.56% | -108.31% | -79.06% | -57.33% |
ROE
-86.1%
ROA
-70.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -86.10% |
| 2026-03-31 | -169.82% |
| 2025-12-31 | -149.80% |
| 2025-09-30 | -113.66% |
| 2025-06-30 | -80.84% |
| 2025-03-31 | -104.28% |
| 2024-12-31 | -76.06% |
| 2024-09-30 | -59.78% |
| 2024-06-30 | -45.10% |
| 2024-03-31 | -34.67% |
| 2023-12-31 | -28.65% |
| 2023-09-30 | -38.83% |
| 2023-06-30 | -33.00% |
| 2023-03-31 | -60.97% |
| 2022-12-31 | -50.68% |
| 2022-09-30 | -59.59% |
| 2022-06-30 | -53.70% |
| 2022-03-31 | -46.41% |
| 2021-12-31 | -39.24% |
| 2021-09-30 | -35.77% |
| 2021-06-30 | -38.04% |
| 2021-03-31 | -34.42% |
| 2020-12-31 | -30.43% |
| 2020-09-30 | -25.05% |
| 2020-06-30 | -20.61% |
| 2020-03-31 | -15.87% |
| 2019-12-31 | -12.25% |
| 2019-06-30 | -23.79% |
| 2019-03-31 | -45.81% |
